Treatment of Overactive Bladder With Anticholinergic Agents

NCT07046156 | Active Not Recruiting FDA Drug

• 1 other identifier: Ivstrh - OAB
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Conditions

Overactive Bladder

Keywords

overactive bladder; children; oxybutynin; propiverine; tolterodine

Outcome Measures

Primary Outcomes (2)

• Number of patients treated with anticholinergic

  6 months

• Number of patients with drug related adverse effects

  1 month

Study Arms (3)

Oxybutynin

Patients treated with oxybutynin

Drug: Oxybutynin Cl

Propiverine

Patients treated with propiverine

Drug: propiverine

Tolterodine

Patients treated with tolterodine

Drug: Tolterodine

Interventions

Oxybutynin Cl DRUG

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

Oxybutynin

propiverine DRUG

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

Propiverine

Tolterodine DRUG

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Tolterodine

Eligibility Criteria

• Age: 5 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Patients who were treated for overactive bladder in pediatric urology clinic of Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital

You may qualify if:

• Patients diagnosed with overactive bladder
• Patients treated with an anticholinergic

You may not qualify if:

• Presence of anatomical or neurological problems
• Patients with missing data

Sponsors & Collaborators

• Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital: lead

Study Sites (1)

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Related Publications (3)

• Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assoc J. 2017 Jan-Feb;11(1-2Suppl1):S74-S79. doi: 10.5489/cuaj.4337.

  PMID: 28265325 BACKGROUND

• Park SJ, Pai KS, Kim JM, Park K, Kim KS, Song SH, Park S, Kim SO, Ryu DS, Baek M, Lee SD, Lee JW, Im YJ, Han SW, Chung JM, Cho MH, Ha TS, Cho WY, Suh HJ; Korean Children's Continence and Enuresis Society. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study. J Korean Med Sci. 2014 Nov;29(11):1550-4. doi: 10.3346/jkms.2014.29.11.1550. Epub 2014 Nov 4.

  PMID: 25408588 BACKGROUND

• Canbaz FA. Response to anticholinergic therapy and its predictors in pediatric overactive bladder. Eur J Pediatr. 2025 Nov 3;184(11):727. doi: 10.1007/s00431-025-06545-3.

  PMID: 41182445 DERIVED

MeSH Terms

Conditions

Urinary Bladder, Overactive

Interventions

propiverine; Tolterodine Tartrate

Condition Hierarchy (Ancestors)

Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phenylpropanolamine; Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines; Benzhydryl Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Cresols; Phenols

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical doctor

Study Record Dates

• First Submitted: June 23, 2025
• First Posted: July 1, 2025
• Study Start: September 1, 2022
• Primary Completion: June 30, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: July 1, 2025

Record last verified: 2025-06

Locations

TU (1)